Abstract
Type 2 diabetes is a chronic disease characterized by insulin resistance, impaired insulin secretion, and hyperglycemia. The long-term complications of diabetic retinopathy, nephropathy, neuropathy, and accelerated atherosclerosis lead to significant morbidity in the form of preventable blindness, end-stage renal disease (ESRD), limb amputations, and premature cardiovascular disease (CVD) [1]. Although patients with diabetes suffer from the morbidity of their microvascular complications, the majority of them ultimately die from the complications of macrovascular coronary artery disease (CAD).
Keywords
- Diabetic Retinopathy
- Impaired Glucose Tolerance
- Diabetes Prevention Program
- Metatarsal Head
- Impaired Insulin Secretion
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
http://diabetes.niddk.nih.gov/DM/PUBS/statistics/ Accessed September 5, 2009.
De Fronzo RA: Lilly Lecture 1987: The triumvirate: β cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988, 37:667–687.
Pratley RE, Weyer C: The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 2001, 44:929–945.
Reaven GM: Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 2005, 47:201–210.
Fagan TC, Deedwania PC: The cardiovascular dysmetabolic syndrome. Am J Med 1998, 105:77 S–82 S.
Wilson PW, D’Agostino RB, Parise H, et al.: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112:3066–3072.
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615–1625.
Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813–820.
UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulfonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837–853.
UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854–865.
UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 7160:703–713.
Buse JB, Ginsberg HN, Bakris GL, et al.: American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007, 115:114–126.
Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403.
Echouffo-Tcheugui JB, Sargeant LA, Prevost AT, et al. : How much might cardiovascular disease risk be reduced by intensive therapy in people with screen-detected diabetes? Diabet Med 2008, 25:1433–1439.
Fong DS, Aiello LP, Ferris FL 3 rd, et al.: Diabetic retinopathy. Diabetes Care 2004, 27:2540–2553..
American Diabetes Association: Position statement: diabetic retinopathy. Diabetes Care 2004, 27:S84–S87.
Gordois A, Scuffham P, Shearer A, Oglesby A: The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complicat 2004, 18:18–26.
American Diabetes Association: Position statement: diabetic nephropathy. Diabetes Care 2004, 27:S79–S83.
American Diabetes Association: Clinical practice recommendations 2009. Diabetes Care 2011, 34:1–61.
Friedman E: Renal syndromes in diabetes. Endocrinol Metab Clin North Am 1996, 25:293–324.
Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253–259.
Harati Y: Diabetic neuropathies: unanswered questions. Neurol Clin 2007, 25:303–317.
Vinik A, Ullal J, Parson HK, et al.: Diabetic neuropathies: clinical manifestations and current treatment options. Nat Clin Pract Endocrinol Metab 2006, 2:269–281.
Frykberg RG, Zgonis T, Armstrong DG, et al.: Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg 2000, 39(Suppl 5):S1–S60.
American Diabetes Association: Position statement: preventive foot care in diabetes. Diabetes Care 2004, 27:S63–S64.
Hidalgo-Tamola J, Chitaley K: Review type 2 diabetes mellitus and erectile dysfunction. J Sex Med 2009, 6:916–926.
Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545–2559.
ADVANCE Collaborative Group, Patel A, MacMahon S, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560–2572.
Duckworth W, Abraira C, Moritz T, et al.: VADT investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129–139.
American Diabetes Association: Position statement: management of dyslipidemia in adults with diabetes mellitus. Diabetes Care 2004, 27:S68–S71.
American Diabetes Association: Position statement: aspirin therapy in diabetes. Diabetes Care 2004, 27:S72–S73.
Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383–393.
Eastman RC, Javitt JC, Herman WH, et al.: Model of complications in NIDDM: Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997, 20:735–744.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Mudaliar, S., Henry, R.R. (2012). Management and Prevention of Diabetic Complications. In: Skyler, J. (eds) Atlas of Diabetes. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-1028-7_11
Download citation
DOI: https://doi.org/10.1007/978-1-4614-1028-7_11
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-1027-0
Online ISBN: 978-1-4614-1028-7
eBook Packages: MedicineMedicine (R0)